NLRP3 and colitis: Recently, JQ1 pretreatment was found to reverse high levels of proinflammatory cytokines, IL-6, IL-1b, and IL-18, in the endotoxemic colon and to reduce the levels of phosphorylated NF-κB and NLRP3/ASC/caspase 1 inflammasome complexes [133], suggesting that JQ1 is a promising target for the treatment of colitis.